Background {#Sec1}
==========

Extracorporeal carbon dioxide (CO~2~) removal (ECCO~2~r) is a technique that allows artificial respiratory support by providing CO~2~ clearance through an extracorporeal circuit, thus unloading the respiratory system. ECCO~2~r has been used during acute respiratory distress syndrome (ARDS) to allow protective ventilation without increasing partial pressure of carbon dioxide (PaCO~2~) \[[@CR1]\]. Other indications include chronic obstructive pulmonary disease (COPD) exacerbation and refractory respiratory acidosis \[[@CR1]\]. Because blood has to proceed through an extracorporeal circuit and filters, proper anticoagulation is needed.

The best anticoagulation strategy for ECCO~2~r is still debated \[[@CR2], [@CR3]\]. We present a case of a patient with COPD with acute respiratory failure who was treated in an intensive care unit (ICU) with ECCO~2~r support using a regional heparin anticoagulation method.

Case presentation {#Sec2}
=================

Our patient was a 56-year-old Caucasian married man with height 172 cm, weight 75 kg, and body mass index 25.4 kg/m^2^. He was admitted to our emergency department for severe dyspnea and desaturation.

The patient had a history of heavy smoking (30 pack-years) and no alcohol intake. In the last year, he had had two hospitalizations for acute exacerbation of COPD and was classified as Global Initiative for Chronic Obstructive Lung Disease class C. He was admitted to the ICU and eventually was tracheostomized. After his ICU stay, he was decannulated and actually showed a former closed tracheal stoma. Moreover, he had type 2 diabetes mellitus and hypertension, and he presented with a former closed tracheal stoma after his last ICU admission for COPD exacerbation. His medication history included ramipril, pantoprazole, and inhalation indacatarol/glycopyrronium.

At arrival, the patient showed hypercapnic respiratory acidosis (pH 7.24, partial pressure of oxygen 45 mmHg, PaCO~2~ 70 mmHg, HCO~3~^−^ 32 mEq/L). Standard medical therapy and noninvasive ventilation (NIV) were immediately started. The result of his neurological examination was normal with a Glasgow Coma Scale score of 15. His heart rate was 106 beats/min, peripheral oxygen saturation was 86%, noninvasive blood pressure was 135/85 mmHg, and body temperature was 37.8 °C. A chest computed tomographic scan showed a centrilobular emphysema and a bilateral fibrothorax (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Chest computed tomography performed on day 1 showing diffused centrilobular emphysema and a fibrothorax aspect. Air bronchograms were evidenced bilaterally at bases

A few hours after admission, the patient was intubated for worsening mental status and worsening respiratory acidosis (pH 7.18, PaCO~2~ 85 mmHg). Mechanical ventilation in pressure support mode was started in the ICU associated with salmeterol and fluticasone 50 μg/100 μg inhalational therapy every 8 h. Sedation was obtained by titrating propofol infusion to obtain a Richmond Agitation-Sedation Scale score of − 1. On the basis of white blood cell count of 22 × 10^9^/L, high procalcitonin serum level 12 ng/ml, and strong suspicion of a pulmonary infection, bronchoalveolar lavage was collected, and intravenous broad-spectrum empiric antibiotic therapy with piperacillin-tazobactam 4.5 g every 8 h and vancomycin 500 mg every 6 h was started. After 72 h, qualitative bronchial cultures showed a negative Gram stain and heavy growth of *Pseudomonas aeruginosa*. At this point, intravenous cefepime 2 g every 8 h was started.

On day 4 after admission, owing to the severity of lung infection, hypercapnic respiratory acidosis worsened to pH 6.98 and PaCO~2~ 157 mmHg despite profound sedation and the maximization of minute alveolar ventilation. A low platelet count of 50,000 cells/μl was recorded. ECCO~2~r was started through a 16-French dialysis bilumen catheter inserted into the right femoral vein using continuous renal replacement therapy (CRRT) (Diapact® system; B. Braun Medical, Milan, Italy) with a Diacap Acute® filter (B. Braun Medical). The extracorporeal circuit was regionally anticoagulated with heparin administered prefilter and protamine sulfate administered postfilter (Fig. [1](#Fig1){ref-type="fig"}).

Table [1](#Tab1){ref-type="table"} shows blood gas analyses before, during, and after ECCO~2~r treatment. The patient's PaCO~2~ dropped to 54 mmHg and pH increased to 7.21 after 6 h of treatment. The Diacap Acute® filter was replaced every 24 h during ECCO~2~r. On day 6 after admission, because PaCO~2~ consistently less than 60 mmHg, ECCO~2~r weaning was attempted, and the patient was switched again into pressure support mode. ECCO~2~r was started again 2 h later because of a rise in PaCO~2~. On day 7 after admission, the patient was successfully weaned from ECCO~2~r. Under pressure support ventilation, he was able to maintain an acceptable PaCO~2~ level (59 mmHg). On day 9 after admission, the patient became febrile with associated hypotension and increased serum lactate level. Multiple organ failure developed during the following 48 h. On day 11 after admission, blood cultures evidenced multidrug-resistant *P. aeruginosa*.Table 1Blood gas analyses before, during, and after extracorporeal carbon dioxide removal with regional anticoagulationBlood gas analysesEDICUDay 1Day 1Day 2Day 3Day 4Day 5Day 6Day 7Day 8Day 9Day 10pH7.247.187.197.126.997.287.307.317.307.287.22PaO~2~70908412510199140119111132143PaCO~2~129114142123157615655585655Post ECCO~2~rFilter changeWeaning trialWeaning trialpH7.297.317.247.30PaO~2~145108129113PaCO~2~54527359ECCO~2~r was started at day 4*Abbreviations: ECCO*~*2*~*r* extracorporeal carbon dioxide removal, *ED* Emergency department, *ICU* Intensive care unit, *PaCO*~*2*~ Partial pressure of carbon dioxide, *PaO*~*2*~ Partial pressure of oxygen

Extracorporeal circuit and anticoagulation technique {#Sec3}
----------------------------------------------------

The extracorporeal circuit was primed two times, first with 1 L of NaCl 0.9% + 10,000 IU of unfractionated heparin and then with 1 L of NaCl 0.9%. A 500-IU/ml heparin solution was prepared and infused prefilter at 0.15 IU/ml/h of blood flow (Fig. [2](#Fig2){ref-type="fig"}). A protamine concentration of 5 mg/ml was infused to match the heparin infusion rate \[[@CR4]\]. ECCO~2~r was started at a blood flow of 300 ml/min and increased slowly to 450 ml/min to maximize CO~2~ removal.Fig. 2Schematic representation of extracorporeal carbon dioxide removal with regional heparin protamine anticoagulation. *PA* Arterial pressure, *PBE* Prefilter pressure, *PV* Venous pressure, *SAD* Safety air detector, *SAC* Safety clamp

Discussion {#Sec4}
==========

To the best of our knowledge, this case report is the first in the literature of regionally anticoagulated ECCO~2~r in a patient with COPD with acute respiratory failure. The main finding in this case report is the efficacy and safety of using ECCO~2~r with a heparin regional anticoagulation regimen.

Severe hypercapnia has several detrimental pathophysiological effects. Accumulation of CO~2~ causes acidosis, reduced consciousness, and an increase in cerebral blood flow due to vasodilation. Moreover, hypercapnic acidosis causes myocardial depression and pulmonary vasoconstriction, raising the risk of both right and left ventricular failure \[[@CR5]\].

First conceived in the late 1970s, ECCO~2~r has been used as an adjuvant respiratory treatment for patients with severe ARDS ventilated with protective ventilation but in need of increasing CO~2~ elimination \[[@CR6]\] and reducing tidal volumes to limit lung damage. More recently, ECCO~2~r has been used for the treatment of severe COPD exacerbations to avoid intubation \[[@CR7]\] or in weaning from mechanical ventilation and as a supportive treatment of severe respiratory hypercapnic acidosis \[[@CR8]\].

Our patient had an acute COPD exacerbation for which NIV treatment failed in the emergency department. Mechanical ventilation in the ICU was challenging because of the patient's obstructive restrictive pattern. Minute ventilation was increased to 13 L/min, reaching safe pressure limits (driving pressure \< 15 cm H~2~O). However, acceptable pH and CO~2~ levels were not obtained. Because standard medical treatment and mechanical ventilation were unsuccessful, ECCO~2~r was started to improve the life-threatening hypercapnic acidosis and potentially injurious mechanical ventilation.

As is true of most continuous venovenous blood purification systems, ECCO~2~r needs anticoagulation to ensure circuit and filter patency. The best anticoagulation strategy is still debated in the literature. A recent systematic review that summarized the evidence about anticoagulation during CRRT indicated that regional citrate-based anticoagulation was the most efficient and safe method \[[@CR2]\]. However, the citrate-based anticoagulation regimen can induce hypocalcemia and metabolic alkalosis. Moreover, in order to reach efficacious venovenous ECCO~2~r, a minimum blood flow of 350 ml/min is necessary. Therefore, citrate could hardly be the anticoagulation mode of choice because of the excessive fluid volume and metabolic load for the body. Indeed, the amount of infused citrate could be above the hepatic metabolic limit, thus resulting in citrate intoxication. Last, postfilter calcium administration could require a massive dosage and a very high speed of infusion to correct the citrate-related hypocalcemia \[[@CR9]\]. Potential hemorrhage was a major concern in our patient because of low platelet count. Thus, in our opinion, regional anticoagulation with heparin and protamine was the best regimen to reduce bleeding risk. Regional heparin-based anticoagulation is widely used in CRRT worldwide \[[@CR4]\]. Nevertheless, in their randomized controlled trial conducted in 2015, Gattas *et al*. compared regional heparin with regional citrate for anticoagulation in CRRT and concluded that an equivalent safety profile and use of citrate allowed a longer CRRT filter life \[[@CR10]\].

Regional heparin anticoagulation is not without risk. Because heparin is supposed to have a longer half-life than protamine, there is a risk of rebound bleeding in cases of incorrect titration. Furthermore, this technique exposes the patient to side effects caused by heparin, such as thrombocytopenia, and to the risks of protamine administration, such as anaphylaxis, hypotension, and pulmonary vasoconstriction \[[@CR11]\]. Nevertheless, most of these drawbacks can be avoided with a slow protamine infusion and a precise heparin-neutralizing protocol.

This case report has limitations. First, we did not perform viscoelastic tests (rotational thromboelastometry or thromboelastography). Moreover, we did not evaluate the heparin-protamine complexes in the patient's blood, so we do not know the serum half-life of the complexes. However, we did not detect any major or minor bleeding event. Daily platelet count and standard coagulation test results were stable and within normal range throughout the treatment.

Conclusions {#Sec5}
===========

With the increasing use of ECCO~2~r, there is a need to increase its safety with regard to anticoagulation. Regional heparin anticoagulation may represent a feasible way to provide ECCO~2~r for CRRT. Adequately powered studies are needed to confirm these observations.
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